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ABSTRACT 24 
The most common causes of urinary tract infections (UTIs) are Gram-negative pathogens 25 
such as Escherichia coli; however, Gram-positive organisms including Streptococcus agalactiae, 26 
or group B streptococcus (GBS), also cause UTI. In GBS infection, UTI progresses to cystitis 27 
once the bacteria colonize bladder, but the host responses triggered in the bladder immediately 28 
following infection are largely unknown. Here, we used genome-wide expression profiling to 29 
map the bladder transcriptome of GBS UTI in mice infected transurethrally with uropathogenic 30 
GBS that was cultured from a 35 year-old women with cystitis. RNA from bladders was applied 31 
to Affymetrix Gene-1.0ST microarrays; qRT-PCR was used to analyze selected gene responses 32 
identified in array datasets. A surprisingly small significant gene list of 172 genes was identified 33 
at 24h; this compared to 2507 genes identified in a side-by-side comparison with uropathogenic 34 
E. coli (UPEC). No genes exhibited significantly altered expression at 2h in GBS-infected mice 35 
according to arrays despite high bladder bacterial loads at this early time point. The absence of a 36 
marked early host response to GBS juxtaposed with broad-based bladder responses activated by 37 
UPEC at 2h. Bioinformatics analyses including integrative systems-level network mapping 38 
revealed multiple activated biological pathways in the GBS cystitis transcriptome that regulate 39 
leukocyte activation, inflammation, apoptosis, and cytokine-chemokine biosynthesis. These 40 
findings define a novel, minimalistic type of bladder host response triggered by GBS UTI, which 41 
comprises collective antimicrobial pathways that differ dramatically from those activated by 42 
UPEC. Overall, this study emphasizes the unique nature of bladder immune activation 43 
mechanisms triggered by distinct uropathogens.  44 
Keywords: Streptococcus, Rodent, Bacterial Infection, Urinary Tract Infection, Escherichia coli, 45 
Inflammation, group B streptococcus, Cystitis, Microarray 46 
47 
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INTRODUCTION 48 
Urinary tract infections (UTIs) are among the most common infectious diseases of 49 
humans with up to 40% of healthy adult women experiencing at least one UTI episode in their 50 
lifetime (24). Gram-negative bacteria, most notably, uropathogenic Escherichia coli (UPEC) are 51 
the leading cause of UTIs. These organisms express a range of virulence factors that provoke 52 
inflammation in the bladder as part of the early steps of UTI pathogenesis (34, 47, 69, 91). Rapid 53 
host inflammatory cascades are initiated in the bladder following UPEC infection, and these 54 
encompass interleukins (8, 51, 52, 68), tumor necrosis factor, nitric oxide (16), and CXC 55 
chemokine receptor 2 (50), among other host factors (7, 65-67). Notably, UPEC may also 56 
suppress innate immune activation as a virulence strategy (7, 41, 75), and roles for immune 57 
suppressive and regulatory elements including Th17 cells and IL-10 were recently shown in the 58 
bladder response leading to UPEC UTI pathogenesis (13, 70). 59 
 60 
Gram-positive pathogens are less frequently associated with UTIs compared to organisms 61 
such as E. coli but are nonetheless common causes of UTI (63). Streptococcus agalactiae, also 62 
known as group B streptococcus (GBS) has emerged in the past ten years as an important Gram-63 
positive uropathogen. GBS is generally associated with maternal cervicovaginal colonization and 64 
disease in newborns and older persons with chronic medical illness (3, 15); however, GBS also 65 
causes acute and sub-acute UTI. GBS UTIs include asymptomatic bacteriuria (ABU), cystitis, 66 
pyelonephritis, and urosepsis, which, clinically, are indistinguishable from UTIs caused by other 67 
uropathogens (46). Urinary GBS is cultured from 1-2% of all cases of clinically suspected UTI 68 
(84), and GBS UTI complicates up to 7% of pregnancies, and may account for up to 10% of 69 
pyelonephritis during pregnancy (46, 54). GBS UTI may also contribute to chorioamnionitis (1), 70 
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premature onset of labour (44), and has been associated with an increased risk of vertical 71 
transmission of the bacteria to infants (55, 90). While the incidence of GBS neonatal disease has 72 
decreased in the past decade, disease in adults such as UTI has increased during this period (15).  73 
 74 
In terms of the mechanisms of virulence and disease underlying GBS UTI, high rates of 75 
ABU among elderly adults (15, 19, 46) prompted a recent survey of the GBS serotypes that 76 
cause UTI, since distinct serotypes of GBS, most notably types III, Ia, and V, are associated with 77 
invasive disease in neonates and adults (84). In that study, a wide-spectrum of serotypes were 78 
shown to cause UTI with a disproportionately high distribution of serotype III isolates associated 79 
with acute disease. The pathogenesis of GBS UTI, however, and the immune responses that are 80 
initiated in the bladder during infection are largely unknown. GBS UTI triggers atypically high 81 
levels of IL-1α (83) and also up-regulates macrophage inflammatory protein-1α (MIP-1α), MIP-82 
1β, IL-9, and IL-10 (35). These findings suggest that, despite GBS UTI being clinically 83 
indistinguishable from UTI caused by other pathogens, divergent mechanisms of pathogenesis 84 
occur in acute UTI caused by this organism.  85 
The paucity of knowledge on pathogenesis in acute GBS UTI prompted us to map the 86 
complete transcriptome of murine GBS cystitis as a means of defining the host pathogen 87 
interactions that occur during early bladder colonization. Comparing overall bladder defense 88 
pathways mounted in response to GBS with those trigged by UPEC on a genome-wide scale 89 
reveals a unique bladder response triggered by GBS that is both more limited in scope and 90 
slower to develop compared to the prototypic Gram-negative uropathogen. This study provides 91 
new insight into host defense strategies in the bladder and uncovers a surprisingly minimal local 92 
transcriptional program in acute GBS UTI that develops in a focused, pathogen-specific manner.  93 
94 
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MATERIALS AND METHODS 95 
Bacteria – The uropathogenic GBS used in this study was cultured from clean-catch voided 96 
urine of a 35 year-old non-diabetic woman with no identified risk factors who presented to the 97 
University of Alabama at Birmingham Hospital with symptoms that were consistent with 98 
uncomplicated cystitis, including dysuria, single-organism bacteriuria >100,000 CFU/ml, and 99 
leukocyte esterase and pyuria (≥10 WBC/µl; non-spun), noted on urinalysis. GBS was grown at 100 
37°C on Todd Hewitt agar or in Todd Hewitt broth. Capsular serotyping was performed as 101 
described elsewhere (84), which identified this isolate as serotype III. Use of the uropathogenic 102 
GBS cultured from the patient in this study was undertaken in accordance with the principles of 103 
the Helsinki Declaration with approval from the Institutional Review Board (IRB) of University 104 
of Alabama Birmingham (UAB) (X070722011) and the Human Ethics Committee (HEC) of 105 
Griffith University (MSC/11/10/HREC). The UAB IRB and the Griffith University HEC waived 106 
the need for specific informed consent. In some comparative assays, we used the prototype 107 
UPEC strain CFT073 (ATCC 700928) which, was cultured from a patient with pyelonephritis 108 
(43). This strain has been used extensively in pathogenesis studies in the murine UTI model (32, 109 
38, 82, 92).  110 
 111 
GBS Adherence to Bladder Uroepithelium – Initially, to determine whether the serotype III 112 
GBS cultured from the patient identified with acute UTI in this study is capable of binding to 113 
human bladder uroepithelial cells in vitro we undertook binding assays using T24 and 5637 114 
bladder cells (ATCC: HTB-4, HTB-9). Thirty thousand T24 or 5637 uroepithelial cells were 115 
grown in poly-D-lysine coated multi-well chamber slides (BD BioCoat) as previously described 116 
(83). FITC-stained GBS (0.25 mg ml-1 in PBS, 15 min, 37ºC) were added (MOI 100 CFU cell-1) 117 
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and after 2h monolayers were rinsed with PBS, fixed for 45 min with 3% paraformaldehyde, and 118 
F-actin was labeled with phalloidin Alexa-594 (Molecular Probes) to co-localize GBS with host 119 
cell surfaces. DNA was counterstained with the nuclear dye Hoechst 33258. Cells were 120 
visualized with a Leica TCS SP2 confocal microscope. Quantitative measurements of GBS 121 
binding to bladder uroepithelial cells were performed using antibiotic protection assays with 122 
5637 cells at 30 min (initial binding), 2h, and 24h (intracellular survival), as described elsewhere 123 
(80). Briefly, 5-8 x 104 uroepithelial cells were seeded into wells of a 24-well tissue culture-124 
treated plate (Nunc), grown for 24h at 37ºC in 5% CO2, and challenged at a multiplicity of 125 
infection of 10 bacteria per uroepithelial cell. After 30 min or 2h, monolayers were rinsed with 126 
PBS (five times) and were either processed for colony counts to determine numbers of adherent 127 
GBS, or fresh media with 100 U/mL penicillin, streptomycin, and gentamicin was added for 128 
subsequent processing at 24h to determine numbers of intracellular GBS (78, 81). For some 129 
assays, supernatants from quadruplicate cultures were collected at 0.5h, 2h, and 24h for analysis 130 
using an 8-target multiplex protein assay (Bio-Rad Laboratories, Gladesville, Australia) to assess 131 
the potential role of bladder uroepithelial cells in the responses to GBS identified by microarrays.  132 
 133 
Murine Model of GBS Cystitis – Female C57BL/6 mice (8-10 wks) were purchased from the 134 
Animal Resources Center (Australia) and Jackson Laboratories (USA). Urine was collected 24h 135 
prior to challenge and examined microscopically and by culture to exclude mice with a 136 
preexisting condition as described elsewhere (85). Mice were anesthetized by isoflurane and the 137 
periurethral area was sterilized with 10% povidone-iodine. Mice were catheterized using a sterile 138 
catheter and 40 μl of PBS containing the challenge inoculum was instilled transurethrally into 139 
the bladder. Control mice received PBS only. For comparisons with UPEC, an additional group 140 
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of mice received an equivalent dose of UPEC CFT073 that was grown at 37°C in Lysogeny 141 
Broth as previously described (13). Urine was collected at 22-24h for colony counts after which, 142 
mice were euthanized and bladders removed and homogenized for counts, or processed for 143 
microscopy to visualize GBS binding to the uroepithelial surface. Escalating dose experiments 144 
were performed to determine the infectious dose (ID)90 of the GBS isolate based on methods 145 
described by Reed and Muench (61). A dose of approximately 3 x 109 CFU was used in most 146 
assays unless otherwise indicated. In some experiments, bladders were collected from mice 30 147 
min after challenge, and were sectioned and washed in PBS (five washes of 5 min, in 1 mL 148 
rotating), then processed as normal to determine the numbers of initially adherent GBS in 149 
bladder. Immunohistochemistry (IHC) was performed on selected bladders for histological 150 
assessment of local cellular infiltrates using standard methods with rat anti-mouse Ly-6g (GR-1) 151 
(eBiosciences, San Diego, CA), and goat anti-rat IgG-FITC (Southern Biotech, Birmingham, 152 
AL) antibodies. Fluorescence dissection stereomicroscopy was performed using an Olympus 153 
SZX16 fitted with a CCD DP72 camera to visualize the distribution of FITC-stained GBS in the 154 
bladder. Brightfield and epi-fluorescence microscopy was performed using an AxioImager.M2 155 
microscope fitted with AxioCam MRm Rev. 3 and MRc 5 cameras (Carl Zeiss, Australia). All 156 
animal studies were performed with approval from and in accordance with the ethical standards 157 
of the Animal Ethics Committee of Griffith University (MSC/14/08/AEC), and the Institutional 158 
Animal Care and Use Committee of UAB (080708186). 159 
 160 
Urine Growth Assays – To determine whether GBS growth in urine could affect the organisms’ 161 
colonization dynamics in the bladder we undertook in vitro urine growth assays. Human urine 162 
was collected from six healthy adult volunteers who had not had UTI or undergone any antibiotic 163 
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treatment in the two weeks prior. Equal volumes of urine were pooled, filter sterilized (0.45 μm) 164 
and stored at 4°C until use (within 48h). Duplicate 200 µl aliquots were inoculated with 165 
approximately 103 CFU of GBS, grown in 96-well microtiter plates at 37°C with shaking (200 166 
rpm), and optical density at 600nm (OD 600nm) was recorded between 0-72h. The growth 167 
experiments were repeated three times and data are shown from one representative experiment. 168 
Ethics approval for use of human volunteer subjects was granted by Griffith University (human 169 
research ethics committee approval #MSC/11/10/HREC). 170 
 171 
Electron Microscopy – For Scanning Electron Microscopy (SEM), whole bladders were 172 
collected from euthanized mice at 2h after transurethral challenge and immediately fixed in 3% 173 
glutaraldehyde in 0.1M cacodylate buffer (pH 7.4) and stored at 4ºC until processing. After 174 
washing in fresh buffer, bladders were pinned onto wax sheets to prevent curling, and post-fixed 175 
in 1% osmium tetroxide, then dehydrated through a graded ethanol series and critical point-dried. 176 
Samples were mounted on SEM stubs and sputter coated with platinum for viewing using a 177 
JEOL 6300F SEM operated at 8 kV.  178 
 179 
RNA Isolation and Microarrays – Total RNA was isolated from GBS-infected, UPEC-180 
infected, and PBS (control) bladders at 2h and 24h after challenge using group sizes of five mice 181 
per treatment group per time point. Total RNA was isolated using Trizol (Gibco) according to 182 
the manufacturers’ instructions, treated with RNase-free DNase, and analyzed using a 183 
Bioanalyzer 2100 instrument (Agilent). RNA that passed Bioanalyzer analysis was quantified 184 
and 100 ng were amplified into cDNA using SuperScript III reverse transcriptase (Invitrogen) 185 
with random hexamers tagged with a T7 promoter sequence. Microarrays were carried out in 186 
quintuplicate for each group and time point using one microarray per mouse (each microarray 187 
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representing one single bladder). This approach provided a high degree of statistical power based 188 
on non-pooled samples to incorporate variance between mice within each treatment group. We 189 
regarded the use of five biological replicates (mice) in each treatment group and time point 190 
preferable to technical replicates, which were not performed.  191 
 192 
qRT-PCR – To interrogate array datasets, qRT-PCR was carried out for selected genes (listed in 193 
Table 1) that were identified as differentially regulated or unchanged following the treatment 194 
according to array analysis. Amplification of cDNA (500ng RNA amplified) was performed 195 
using a GeneAmp 7700 System (Applied Biosystems). Target genes were amplified using 196 
thermal cycling conditions previously described (13, 83). Glyceraldehyde-3-Phosphate 197 
Dehydrogenase (GAPDH) and β-actin were used as reference genes. Primer sequences for each 198 
target gene are shown in supplementary Table S1. Separate reactions were carried out to ensure 199 
that the efficiency of amplification of the reference gene was approximately equal to that of the 200 
target gene. Relative expression levels of target genes were determined by normalizing reaction 201 
CTs to the housekeeper genes, GAPDH and β-actin. ΔCT values were used in the formula 2.0–202 
[ΔCt] for calculation of the relative mRNA expression levels of target genes as previously 203 
described using PCR efficiencies and mean crossing point deviations between samples and 204 
controls (56, 57).  205 
 206 
Statistical Analysis and Bioinformatics – Data preprocessing: raw microarray data were 207 
normalized using quantile normalization and summarized using RMA in the affy package in 208 
Bioconductor (http://www.bioconductor.org), as described elsewhere (13). Differentially 209 
expressed genes were identified by analyzing data using the MAANOVA package 210 
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(http://www.bioconductor.org/packages/bioc/1.8/html/maanova.html). To identify significant 211 
changes in expression induced by GBS, we used a shrinkage based t test together with 212 
permutation (9, 10).  A false discovery rate (FDR) of 0.1 was used to generate the significant 213 
gene list. Gene class testing was performed using the SAFE package in Bioconductor by 214 
applying thresholds to select significant pathways (4). Both Kyoto Encyclopedia of Genes and 215 
Genomes (KEGG) (29, 48) and Gene Ontology (GO) (2) were used to generate a signaling 216 
network from the gene class analysis. FDR 0.1 was used as a cut off for both tools. GoMiner was 217 
used to analyze functional groups of genes activated in biological pathways and generate VENN 218 
diagrams of functionally related responses. InnateDB (http://innatedb.ca) was used to provide an 219 
integrative systems-level analysis of functional groups activated within biological pathways. 220 
Over-representation analysis (ORA) of pathways in innateDB using significant gene lists was 221 
performed using the hypergeometric algorithm and Benjamini Hochberg correction method with 222 
pathway ORA p-value significance set at 0.05. 223 
224 
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RESULTS 225 
Colonization of Uroepithelia by Serotype III GBS in vitro and in vivo – Binding assays using 226 
human T24 and 5637 bladder uroepithelial cells showed adherence of serotype III GBS to cells 227 
30 min after infection (Figure 1A and B; T24 cells shown). These results are consistent with 228 
results previously reported for serotype II GBS (83). Changes in cellular architecture were noted 229 
in some cells to which GBS had bound (compare Figure 1A and C). Similar results were 230 
observed in 5637 bladder cells (not shown). In the murine model, the serotype III GBS isolate 231 
was observed bound directly to the bladder uroepithelium at 2h following transurethral infection. 232 
Colonization was observed as focal areas of adhesion across the bladder surface that was 233 
visualized using fluorescence dissection stereomicroscopy to detect FITC-GBS (Figure 1D-E). 234 
Resected areas of bladder processed and imaged using high resolution SEM confirmed binding 235 
of serotype III GBS to the uroepithelium in vivo as early as 2h following challenge (Figure 1F-236 
G). Histological assessment of control (Figure 1H-J) and GBS-infected (Figure 1K-M) bladders 237 
using hematoxylin and eosin (H&E, panels H, K) staining illustrated a local cellular infiltrate at 238 
24h that was comprised of polymorphonuclear leukocytes (PMNs), as shown by IHC staining 239 
specific for PMNs (Figure 1, compare control panels I-J and GBS-infected panels L-M).  240 
 241 
Quantitation of initial binding of GBS to human bladder uroepithelial cells immediately 242 
after infection in vitro showed that 0.15% of the total bacteria used for challenge bound to 243 
bladder cells after 30 min (Figure 2). This percent adherence was higher than that of UPEC 244 
CFT073 at 30 min although this difference was not statistically significant. A notable difference 245 
was observed after 2h of infection, in which GBS remained at 0.15% adherence/invasion, but 246 
UPEC had increased to 2.5% adherence/invasion (Figure 2). Intracellular survival, measured at 247 
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24h after antibiotic protection, showed that GBS was recovered from the intracellular 248 
compartment of host cells after 24h in numbers comparable to that of UPEC (Figure 2). Thus, 249 
GBS binds to human bladder uroepithelium in vitro within 30 min, invades these cells, and is 250 
able to survive intracellular for at least 24h at levels comparable to UPEC. There is however, a 251 
significant difference in adherence/invasion between these organisms when measured at 2h.    252 
 253 
Escalating dose assays in mice demonstrated that the ID50 and ID90 of the GBS in this 254 
study were 1.2 x 109 and 2.9 x 109 CFU, respectively (Figure 3A). Quantitation of bacterial loads 255 
in mice that received 3 x 109 CFU (taken as the ID90) demonstrated efficient binding of GBS to 256 
the surface of the bladder uroepithelium in vivo after 30 min (Figure 3B). The majority of GBS 257 
present in the bladders of mice at 30 min after challenge represented bound bacteria, since there 258 
was no difference in total bladder load between tissues that were unwashed (U/W) and those that 259 
were extensively washed (W). The differences between U/W and W bladders from mice infected 260 
with UPEC CFT073, on the other hand, were significant (p=0.015, Figure 3B), illustrating at 261 
least equally efficient binding of GBS to the bladder uroepithelium surface in vivo as compared 262 
to UPEC. The average bladder GBS burden after 2h was 106 CFU/0.1g tissue (Figure 3C), which 263 
decreased 100-fold after 24h. The decreases in GBS in bladder between 2h, 24h, and five days 264 
were statistically significant (p<0.05), demonstrating a decline in bacterial burden over time to a 265 
point at the end of the assay (5 days) when most mice were bladder culture-negative. A few mice 266 
exhibited positive kidney cultures at 2h, 24h, and five days (Figure 3D); however, there were no 267 
significant differences in the mean recovery of GBS from kidneys between any of these time 268 
points. High numbers of GBS were detected in the urine at 2h and subsequently declined by 24h, 269 
but then exhibited equivalent mean bacteriuria levels between 24h and five days (Figure 3E).  270 
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 271 
We also sought to determine whether GBS might replicate in urine in the bladder to 272 
evaluate whether the dynamics of uroepithelium colonization might be affected by growth in 273 
urine, as occurs for E. coli (33, 64, 89). In vitro growth assays performed with GBS using fresh 274 
human urine demonstrated virtually no bacterial replication over a time course of 72h (Figure 275 
4A). Similar data were observed for growth curves performed using fresh urine from C57BL/6 276 
mice (not shown). In contrast, we observed rapid growth for both control E. coli strains that were 277 
used in these assays (Figure 4A). To investigate any general growth defect, we also performed 278 
parallel growth curve assays using rich THB media. However, there was no general growth 279 
defect in the uropathogenic serotype III GBS in THB (Figure 4B). Together, these data show that 280 
GBS is unable to replicate in urine, and growth in urine is unlikely to influence the dynamics of 281 
uroepithelium colonization during GBS UTI in mice.  282 
 283 
GBS Cystitis Transcriptome – Initial genome-wide expression profiling of bladder 284 
failed to identify any genes with significantly altered expression immediately after GBS infection 285 
at 2h. This finding was unexpected and relatively surprising given the peak bladder bacterial 286 
burdens that were detected at this early time point (Figure 3C) and an overall lower variance in 287 
total bladder-urine bacterial loads between mice within the 2h group compared to later time 288 
points. In contrast to microarray datasets at 2h, comparisons of infected and control mice at 24h 289 
revealed a diverse set of 172 genes with significant changes in expression (FDR ≤0.1). Heat 290 
maps for arrays illustrating overall gene signal intensities in the samples at 24h are shown in 291 
Figure 5A, alongside a volcano plot illustrating the overall breadth of the GBS bladder 292 
transcriptome at 24h in Figure 5B. The complete significant gene list at 24h is listed in Table 2. 293 
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A summary of the gene expression changes plotted according to FDR for the top 75 genes (FDR 294 
≤0.05) are shown in supplementary Figure S1 alongside a VENN diagram derived using 295 
GoMiner for the general responses related to defense to bacteria, cytokines, and inflammation. 296 
The raw datasets for array comparisons are deposited on the Gene Expression Omnibus under 297 
record GSE27575 (http://www.ncbi.nlm.nih.gov/geo/).  298 
 299 
Overall, the GBS cystitis transcriptome comprised genes encoding multiple mediators of 300 
defense including those known to be responsive to GBS in other models of infection including 301 
IL-1α (3.7, 0.035), IL-1β (10.1, 0.011), IL-6 (3.3, 0.093), Stat1 (4.5, 0.03), Stat2 (3.11, 0.04), 302 
Ccl5 (2.10, 0.044), and multiple PARPs (5, 20, 23, 31, 49, 58, 77, 81, 83) (fold-change, FDR). 303 
Other genes that encode ILs and their receptors or receptor antagonists were also identified in the 304 
transcriptome including IL-1 family member 9 (4.7, 0.033), IL-1r antagonist (1.8, 0.082), IL-2rg 305 
(3.4, 0.048), and IL-13ra1 (3.0, 0.088). Chemokine and chemokine receptor genes were also 306 
prominent including Cxcl10 (25.4, 0.006), Cxcl5 (4.27, 0.071), Cxcl9 (3.99, 0.075), and Ccl12 307 
(2.9, 0.078). Other genes of note were several that encode apoptosis regulators and effectors 308 
including PARP family members 9 (2.8, 0.058), 12 (2.5, 0.053), and 14 (3.1, 0.088), CARD 5 309 
(3.0, 0.035), and neutrophil apoptosis (3.3, 0.093), given the ability of GBS to induce apoptosis 310 
and PARP cleavage (79). Surprisingly, several prominent antibacterial defense molecules that 311 
have been associated with GBS in other infection models in prior studies such as iNOS (78) and 312 
TNF-α (27) were not detected as significantly altered in expression in the bladder transcriptome.  313 
 314 
qRT-PCR – qRT-PCR showed that expression levels of selected target genes were consistent 315 
with individual gene responses identified using microarrays. For example, Cxcl10, which was 316 
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the most strongly activated gene induced by GBS according to microarrays at 24h (25.40 fold-317 
increase, p=0.006; Table 2), was also highly expressed according to qRT-PCR (Table 1; 30.75 318 
fold-increase, p=0.001). Similarly, multiple other genes including those that encode iNOS, 319 
CCL5, CXCL5, CXCL9, IL-6, IL-1α, and IL-1β were up-regulated according to both qRT-PCR 320 
and microarrays. As expected, there were a number of genes that were tested by qRT-PCR that 321 
exhibited higher fold-increases compared to microarrays because PCR is more sensitive than the 322 
arrays (Table 1 and data not shown). All these transcripts were detected at several cycles above 323 
background levels, which validates the detection of genes with low Ct values (e.g. IL-6). The 324 
housekeeping genes β-actin and GAPDH, which were unchanged in microarrays, also showed no 325 
significant changes according to qRT-PCR. This was consistent with several other genes that 326 
showed no significant changes in expression according to microarrays and no significant changes 327 
according to qRT-PCR, including the genes for EMR1, CSFR1, INFGr1, and Caspase-3.  328 
 329 
Bioinformatics Analysis of Biological Pathways in the Transcriptome – Initial analysis of 330 
biological pathways within the GBS cystitis transcriptome by gene class testing using the KEGG 331 
database identified no significant interactions with p values <0.25 for comparisons between 332 
infected and control mice at 2h. In contrast, there were 34 significant KEGG pathways that were 333 
identified using the 24h datasets (Table 3). The most strongly represented pathways at 24h were 334 
those related to host responses to bacterial infection; for example, pathways for metabolism (561, 335 
562, 630), ABC transport (2010), focal adhesion (4510), extracellular matrix receptor 336 
interactions (4512), Toll-like receptors (TLRs) (4620), NK cell-mediated cytotoxicity (4650), 337 
and B cell receptor signaling (4662) were all significantly over-represented. Others of interest 338 
were those for MAPK signaling (4010), apoptosis (4210), T cell receptor signaling (4660), 339 
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antigen processing and presentation (4612), and cytokine-cytokine receptor interactions (4060).  340 
 341 
Subsequent GO biological process analyses of the microarray data for GBS-infected mice 342 
at 2h and 24h, shown in supplementary Table S2, revealed a larger number of over-represented 343 
pathways compared to those derived by KEGG as above: 40 and 278 at 2h and 24h (p<0.05), 344 
respectively. Interestingly, several pathways identified at 2h using GO indicated that GBS might 345 
suppress early host responses in the bladder following infection. These pathways included those 346 
related to down-regulation of the defense response (0031348), down-regulation of the response 347 
to stimulus (0048585), and down-regulation of the inflammatory response (0050728) (Table S2), 348 
which are all pathways consistent with regulation of early inflammatory responses. Pathways 349 
related to immune activation and up-regulation of antimicrobial defense were highlighted at 2h 350 
but were more prominent at 24h. These included pathways for T-lymphocyte mediated immunity 351 
(0002456), nitric oxide synthesis (0006809), TNF-alpha production (0032640), and up-352 
regulation of the innate immune response (0045089). Concomitant activation of immune-353 
suppressive pathways for adaptive responses (0002820) and cytokine synthesis (0042036) were 354 
also identified at 24h indicating a balance of pro- and anti-inflammatory responses.  355 
 356 
Integrated Systems-Level Analysis – We next used the InnateDB database as a complementary 357 
bioinformatics tool to enable integrative systems-level analyses of the array data. This identified 358 
293 distinct biological pathways at 24h, which included an additional 15 pathways compared to 359 
those that were identified using GO. Mining of the data within InnateDB by ORA analysis 360 
identified 168 over-represented pathways at 24h (p<0.05; supplementary Table S2). The most 361 
significant of these with the highest number of activated genes were those for cytokine receptor 362 
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interactions (604) and chemokine signaling (4351), shown in Figure 6. Many of the interactors in 363 
the pathways that were identified exhibited a large number of interactions such as TRAF6 (525 364 
interactors) although others exhibited fewer interactors such as TNF (39), and TLR-9 (16).  365 
 366 
Common and Unique Elements of the GBS Bladder Transcriptome – Direct comparisons of 367 
gene expression responses in bladders of mice challenged with GBS and UPEC enabled us to 368 
ascertain the degree of response conservation in the bladder transcriptome. These comparisons 369 
used bladders from GBS-infected, UPEC-infected, and PBS control mice in a single experiment 370 
and control group to map gene expression responses, and fold-changes. An absence of significant 371 
changes in gene expression induced by GBS in the bladder at 2h according to array analysis 372 
contrasted strikingly with data obtained from mice infected with UPEC for 2h. These data, 373 
recently published, showed that mice with UPEC UTI exhibit a bladder transcriptome at 2h that 374 
comprises 1564 transcripts with significant fold differences compared to controls (13). 375 
Microarray analysis in the current study showed that, in contrast to the 172 significant changes in 376 
gene expression triggered by GBS at 24h (Table 2), UPEC induced 15-fold more significant 377 
changes in gene expression at this time point. The 24h bladder transcriptome of UPEC UTI in 378 
C57BL/6 mice revealed a significant gene list of 2507 genes (FDR ≤0.05), which is shown in 379 
supplementary Table S3. Raw array data for UPEC infected mice at 24h are deposited on Gene 380 
Expression Omnibus under record GSE27575, and data defining bacterial loads in these mice, 381 
along with 2h array datasets, are described in (13).  382 
 383 
Comparative bladder transcriptional responses triggered by GBS and UPEC at 2h and 384 
24h are illustrated by Volcano plots in Figure 7. These plots highlight the total number of shared 385 
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gene expression responses that we identified as commonly induced/repressed by both pathogens 386 
at 24h (FDR<0.05), and also illustrate the much larger number of microbe-specific gene 387 
expression patterns that were induced in the bladder at 24h. The total bladder gene expression 388 
responses that were common to both GBS and UPEC cystitis models at 24h comprised only 68 389 
genes, and these are listed in supplementary Table S4. The slower bladder response to GBS 390 
(Figure 7A-B) compares to a more rapid and broader response initiated by UPEC (Figure 7C-D).  391 
 392 
Bladder Uroepithelial Cells Provide Defense against GBS – Finally, we undertook an analysis 393 
of GBS-infected human bladder 5637 uroepithelial cells in vitro to assess whether uroepithelial 394 
cells might contribute to the responses that we observed in the bladder transcriptome in mice. For 395 
this, we used a multiplex bead-based analysis of cell culture supernatants and compared the 396 
response of infected cells to control (non-infected) cells for a panel of 8 protein targets that were 397 
selected on the basis of significant gene responses in the bladder transcriptome and histology. 398 
These experiments were also performed in parallel with UPEC for direct comparisons. The data, 399 
shown in Figure 8, illustrate that human uroepithelial cells contribute to host defense against 400 
GBS through the production of several cytokines including IL-1β, and IL-1ra, which are protein 401 
responses consistent with gene expression patterns observed in mice. Increased production of the 402 
chemokine IL-8 in bladder uroepithelial cells at 24h in response to GBS (Figure 8) correlated 403 
with the PMN infiltrate observed in the bladder of mice at 24h (Figure 1). Comparing these 404 
overall responses to those triggered by UPEC showed that most, but not all targets proteins, were 405 
induced more strongly by UPEC. These included IL-8 and GM-CSF, but not IL-1β or IL-1ra. 406 
Other target proteins including IL-6, IL-13, IL-17, and CCL5 were not induced by GBS over the 407 
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time course in the human cell culture model, even though these, or closely related factors (e.g. 408 
IL-13ra1, IL-17rd), were significantly induced or repressed in the GBS bladder transcriptome.  409 
410 
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DISCUSSION 411 
Cystitis due to bacterial infection stems from microbial adherence to uroepithelial cells, 412 
which facilitates resistance to the natural hydrodynamic forces of urine flow that remove 413 
potential pathogens from the bladder. Uropathogenic GBS was shown to adhere to uroepithelial 414 
cells more efficiently compared to non-uropathogenic GBS in a prior study (83), and the 415 
organisms’ hemolysin-cytolysin was shown to contribute to the pathogenesis of UTI in mice 416 
(35). However, the early events in bladder colonization and the mechanisms of host defense 417 
activated immediately following infection with GBS are largely unknown. The results of the 418 
current study show that GBS is able to bind to mouse and human bladder uroepithelium rapidly, 419 
within minutes of infection, and relatively efficiently compared to the most well adapted 420 
bacterial uropathogen, UPEC. This study also shows for the first time, that GBS is able to invade 421 
human bladder uroepithelial cells, and is able to survive inside these cells for at least 24h, which 422 
may contribute to UTI pathogenesis. Adherence to and invasion of bladder uroepithelium sets the 423 
stage for progression to cystitis once the bacteria are detected by innate immune surveillance 424 
mechanisms.  425 
 426 
Innate immune signalling cascades are initiated within hours of contact with bacterial 427 
pathogens in various infectious settings (17, 18, 71, 95, 96), and are induced in the murine 428 
bladder within 2h of UPEC UTI (13). Such rapid inflammatory responses in the bladder in 429 
response to UPEC are exemplified by a thousand-fold increase in TNF-α at 1h post-infection, 430 
which precedes high bladder bacterial loads at one day (28), and induction of CXCL1, CXCL6 431 
and MIP-2 within 4h (7, 25). Surprisingly, despite substantial GBS bladder burdens early in the 432 
course of UTI in this study, GBS failed to trigger robust inflammation within 2h of infection in 433 
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mice according to genome-wide transcriptomic analysis. Thus, GBS UTI contrasts with UPEC 434 
UTI in terms of higher GBS bladder burdens very early during infection, which precede the bulk 435 
of inflammatory responses that occur at 24h post-infection. Our data also indicate that GBS 436 
bladder burdens are not influenced by the presence of urine because the bacteria could not utilize 437 
this for growth in vitro, in contrast to UPEC. High GBS loads observed at 2h in this study are 438 
consistent with recent findings of high bladder bacterial loads in C3H/HeN mice at 3h (35) that 439 
progressed with relatively mild immune responses in the bladder. Taken together, this suggests 440 
that the dynamics of early GBS bladder colonization are similar in these two strains of mice.  441 
 442 
This study also shows that innate bladder responses to GBS unfold slowly compared to 443 
UPEC, and the breadth of the response to GBS is more limited in scope. The nature of the 444 
pathogen-specific response during cystitis in mice due to these two organisms is unmistakable 445 
because of the comparative analyses that were undertaken in parallel across the entire genome. 446 
We chose to administer the same infectious dose for both organisms in terms of cell number for 447 
our microarray experimental design in order to precisely control this comparison. However, it 448 
would also be interesting to compare gene expression responses in mice given lower doses of 449 
UPEC, which, based on prior observations, would be closer to the ID90 for this pathogen. Our 450 
comparisons identified only 68 shared gene expression responses induced by both GBS and 451 
UPEC, which illustrates that the majority of gene expression changes in the bladder triggered by 452 
these organisms are pathogen-specific. The bioinformatics findings in this study are of particular 453 
interest because they reveal a marked induction of innate defense mechanisms against GBS in 454 
UTI that are essentially unknown in host responses to GBS in general. Some of these, such as 455 
ABC transporters, have prominent roles in infectious diseases pathogenesis in other settings, and 456 
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these will be of interest in future GBS host-pathogen studies. Other biological pathways 457 
identified as enriched in the GBS bladder transcriptome by KEGG such as TLRs are well-458 
established elements of defense against GBS in non-UTI models both in vitro and in vivo.  459 
 460 
A relatively slower and milder innate immune response triggered by GBS compared to 461 
UPEC could influence the survival of GBS in the bladder immediately after colonization of the 462 
uroepithelium. Interestingly, human blood cultures exposed to GBS also exhibit a delayed 463 
pattern of pro-inflammatory cytokine induction including IL-1β and IL-6, which are not 464 
produced until 24h (86, 87). Comparison of bladder responses to GBS with non-UTI models 465 
reveal other commonalities in the transcriptome reported here; IL-6 in GBS sepsis (5, 20, 49) for 466 
example, and CCL5, Stat1, Parp9, IL-1β and Nos2 (23, 31, 58, 77, 81, 83). Factors that might 467 
contribute to tissue damage in the bladder during GBS cystitis were also shown to be induced 468 
including multiple CXC chemokines such as CXCL10 (36), as well as IL-1β (11), and Nos2 (45). 469 
Importantly, however, it should be noted that these factors mediate antimicrobial defense in 470 
some infections and thus, may be important for disease control in GBS UTI. CXCL10 and Nos2, 471 
for example, aid in controlling Gram-negative uropathogens in the bladder (53). The functional 472 
contribution of many of these factors in the GBS bladder transcriptome to the progression of UTI 473 
can now be investigated based on their expression kinetics as shown in this study.  474 
 475 
In terms of UTI pathogenesis in general, different microbes have been strongly linked to 476 
host features relevant to disease (76), which underscores the importance of host factors in both 477 
controlling and contributing to disease. Several studies have described pathogen-specific 478 
immune responses in the urinary tract, and these offer valuable insight into the results of the 479 
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current study. In a recent study on upper UPEC UTI, a new TLR-4/interferon regulatory factor 3 480 
(IRF3)-dependent pathway of pathogen discrimination was defined (21). Pathogen-specific 481 
responses to UPEC were previously associated with mucosal TLR responses involving TLR-4-482 
dependent, LPS/CD14-independent defense (22, 26), as reviewed elsewhere (60). In the newly 483 
described model, commensal E. coli selectively engaged receptors that drive IRF3 activation by 484 
UPEC, leading to epithelial gene transcription in a pathogen-specific manner (21). In the current 485 
study, GBS did not trigger IRF3; however, IRF1 and IRF7 were activated transcriptionally. This 486 
implies that mechanisms involving IRF1 and IRF7, which are involved in prominent signaling 487 
events in the GBS bladder transcriptome such as CXCL10 (88, 94), may drive immune 488 
engagement in the bladder early during GBS UTI. Thus, further studies will be of interest to 489 
address the potential role of interferon regulatory factors in GBS UTI.  490 
 491 
TLR signaling genes were identified as over-represented in several biological pathways 492 
in the GBS bladder transcriptome according to innateDB, which was used to gain insight into 493 
networks relevant to innate immunity beyond KEGG and GO (39, 40). Whilst there remains 494 
debate around how GBS initiates innate immune responses, there is consistency around an 495 
important role for TLR-2. In systemic GBS infection, TLR-2 deficiency is associated with 496 
impaired host resistance (59); in peritoneal macrophages GBS induces TLR-2-dependent gene 497 
activation (12), and in a neonatal infection model, TLR-2 was necessary for GBS clearance (42). 498 
There is little published data on TLR-2 signaling in the bladder, however, a body of recent 499 
evidence suggests that TLR-4 is central to the induction of local innate immunity (60, 72, 73, 500 
93). TLR-4- and CXCR1-deficiency predisposes to asymptomatic carriage of E. coli, and 501 
possibly other, uropathogens (60). In this study, GBS up-regulated the genes for TLRs-2, -11, -1 502 
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and -6 marginally but none of these responses were statistically significant. InnateDB identified 503 
interactions involving TLR-9 suggesting recognition of unmethylated CpG GBS DNA. Up-504 
regulation of many IL-1 family members in the GBS bladder transcriptome also suggests 505 
potential involvement of TLR-2, especially considering recent reports on the up-regulation of IL-506 
1 through TLR-2 in response to intracellular infection (37) and Borrelia (6). It is also valuable to 507 
interpret these data for GBS against those described for enterococci in mice, which revealed 508 
TLR-2-independent inflammation during pyelonephritis (30). In GBS UTI, up-regulation of 509 
TLR-2 might occur later during infection (after 24h), or may act in signal transduction in the 510 
absence of up-regulation. However, an absence of significant up-regulation of TLR-2 early 511 
during UTI may also explain the relatively slow bladder immune response to GBS, and the high 512 
incidence of GBS ABU that is observed clinically (84).  513 
 514 
In this study, we observed a number of important correlations between the GBS bladder 515 
transcriptome in mice and protein production in human bladder uroepithelial cells that were 516 
challenged with GBS in vitro. This is the first report, to our knowledge, that human bladder cells 517 
contribute to defense against GBS through the production of cytokines and chemokines including 518 
IL-1β, IL-1ra, and IL-8. Some of these findings, such as that for IL-8, support our histopathology 519 
observations of a notable PMN inflammatory infiltrate in the bladder of mice after one day of 520 
GBS UTI. Other findings in the human bladder cell culture model however, such as an absence 521 
of response for CCL5, and other factors related to genes identified as significant in the bladder 522 
transcriptome (e.g. IL-13 and IL-17), suggest limitations of this in vitro model. Here, it is 523 
important to underscore the limitations of epithelial cell monoculture models for the host 524 
response studies; cell-cell interactions, for example, are often necessary to generated effective 525 
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antibacterial responses, as reviewed elsewhere (14). The timing and duration of infection in such 526 
models can also influence bacterial adherence to (and invasion of) host cells, as demonstrated in 527 
the present work for UPEC (0.5h vs. 2h), and this could alter cytokine responses. In these assays, 528 
we tested culture supernatants at 0.5h, 2h, and 24h, but it is plausible that these responses could 529 
differ depending on the timing of infection. Moreover, many cell types that would be present in 530 
the infected bladder in vivo such as resident macrophages, lymphocytes, and PMNs as well as 531 
other infiltrating cells were excluded from the human cell culture model. Thus, the contribution 532 
of these cells to defense, and the role of cytokines produced by human bladder cells to UTI, will 533 
require further investigation. Importantly, however, several pathogen-specific responses were 534 
also evident in the human bladder cell response (e.g. IL-1β, IL-1ra), which supports the distinct 535 
bladder transcriptomes for GBS and UPEC observed in mice. Finally, one must consider species 536 
differences between mouse and human when extrapolating protein expression data from human 537 
bladder cells in culture to data derived from mouse infection assays. The lack of IL-1β protein 538 
detected at 24h in the human cell culture model in the study, for example, contrasts with high 539 
levels of this cytokine induced by both GBS and UPEC in mice at 18-24h during cystitis (83). 540 
However, these distinctions may reflect any of the multiple limitations inherent in these models 541 
as described, and such comparisons are therefore only valid in view of these various limitations.  542 
 543 
Several recent studies on immune responses to bacterial uropathogens have investigated 544 
these responses in relation to the degree of immune activation in the urinary tract and the control 545 
of disease. In Ureaplasma parvum UTI, for example, complications of infection were shown to 546 
depend on host factors related to exaggerated, as opposed to minimal, immune responses (62). In 547 
that study, animals that developed asymptomatic, rather than acute, UTI exhibited divergent non-548 
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PMN related responses in the urinary tract. More minimalistic immune responses led to a higher 549 
rate of pyelonephritis in infected animals. These findings support the notion that the degree of 550 
host response contributes to the pathogenesis of bacterial UTI, as discussed elsewhere (74). In 551 
the current study, only a few mice exhibited positive kidney cultures following challenge with 552 
GBS despite all mice harboring high GBS bladder burdens at 2h, and most exhibiting moderate 553 
bladder and urine burdens at 24h. This suggests that that the early immune responses activated 554 
by GBS in the bladder are mostly effective in preventing ascension of the bacteria to the kidneys. 555 
It is important to note, however, that GBS kidney colonization may differ between mouse strains, 556 
and pyelonephritis is more prevalent in C3H/HeN mice, which exhibit inflammation and a 557 
cellular infiltrate (35). These data imply that microarray mapping of GBS pyelonephritis in mice 558 
would be useful to define immune activation in this condition; this, however, would ideally be 559 
undertaken using a more consistent model of upper UTI than that described in the current work.   560 
 561 
Finally, our data support the observations of a recent study that showed that GBS 562 
stimulates and suppresses immune activation simultaneously, through distinct pro- and anti-563 
inflammatory mechanisms in the bladder (35). Our bioinformatics findings based on GO showed 564 
that GBS activates biological pathways related to down-regulation of defense, and down-565 
regulation of inflammation early during infection. However, GBS also triggered pathways of T-566 
lymphocyte mediated immunity, nitric oxide synthesis, and TNF-alpha production. Collectively, 567 
these results confirm that GBS simultaneously suppresses and activates bladder inflammation.  568 
 569 
In summary, this study defines a minimalistic, pathogen-specific bladder transcriptome of 570 
GBS cystitis. Many of the factors identified within this response will require future investigation 571 
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to define their potential roles in defense against GBS UTI. Overall, this study offers critical new 572 
perspective on the uniqueness of bladder responses to different uropathogens, and, more broadly, 573 
highlights the distinct mechanisms of UTI pathogenesis induced by different bacteria. 574 
  575 
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FIGURE LEGENDS 891 
Figure 1: Attachment of uropathogenic serotype III GBS to human bladder uroepithelial cells in 892 
vitro (A, 30 min; B, 2h; C ctrl) and colonization of the surface of bladder uroepithelium in 893 
murine GBS UTI as analyzed by fluorescence microscopy on whole tissue illustrating focal areas 894 
of adhered GBS (D-E) alongside images of pockets of bound GBS between folds of 895 
uroepithelium (F-G) as analyzed with high resolution SEM. Histological assessment of control 896 
(H-J) and GBS-infected (K-M) bladders illustrates a PMN infiltrate at 24h (arrowheads), as 897 
demonstrated in serial sections stained using either H&E (H, K), or PMN-specific Gr-1 antibody 898 
using IHC techniques (I-J, L-M). Scale bars are 50 μM (small bars) and 180 μM (large bars) 899 
 900 
Figure 2: Quantitation of adherence and intracellular survival of serotype III GBS in human 901 
bladder uroepithelial cells in vitro. The percentage of bacteria bound to 5637 cells after 30 min 902 
(representing initial adherence) is shown for GBS (A), alongside the percentage bound and 903 
invaded at 2h, and the percentage of intracellular bacteria recovered from bladder cells after 24h 904 
after antibiotic protection. The equivalent data for UPEC CFT073 are shown for comparison (B) 905 
 906 
Figure 3: Infectious dose and temporal colonization dynamics of uropathogenic serotype III 907 
GBS in a murine model of UTI. Data for escalating dose assays (A), and measures of early 908 
bladder adherence of GBS in mice challenged with the ID90 after 30 min (B) are shown alongside 909 
persistence data for GBS in the bladder (C), kidneys (D), and bacteriuria levels (E). Broken lines 910 
indicate the detection limit for each sample type based on the volumes plated. Initial binding of 911 
GBS to bladder uroepithelium in (B) was determined by comparing unwashed (U/W) bladders 912 
(bound GBS plus those present in bladder lumen) (n=6) with washed (W) bladders (representing 913 
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only adherent bacteria after 30 min), and are shown alongside data for UPEC for comparison. 914 
Temporal colonization data (C, D, E) represent pooled data from mice challenged with ID90 in 915 
two separate experiments with at least 9 mice per group per experiment. Statistical comparisons 916 
between groups are based on Mann-Whitney U tests with p values set for significance at 0.05 917 
 918 
Figure 4: In vitro growth curve assays of uropathogenic serotype III GBS in pooled human urine 919 
(A), and in THB (B) as measured at OD600 nm. The equivalent growth curve data derived from 920 
control E. coli strains UPEC CFT073 and 83972 in parallel assays are shown for comparison 921 
 922 
Figure 5: Global gene expression in bladder during GBS cystitis in mice comprises a significant 923 
list of 172 genes (FDR<0.1) derived from comparisons of infected and control mice at 24h (n=5). 924 
Gene signal intensities are illustrated in the heat maps for individual arrays (A). The complete 925 
significant gene list is provided in Table 2. The summary response is shown using a volcano 926 
scatterplot (B) where significant genes are displayed as shrinkage t-test results [-log10(Pvalue)] 927 
(y-axis) vs. expression ratio (log2(mean GBS infected / control)) (x-axis) with vertical lines 928 
representing a 2-fold difference; red stars represent FDR<0.1 929 
 930 
Figure 6: Immune activation in the GBS UTI transcriptome comprises prominent cytokine-931 
cytokine receptor signaling (innateDB pathway number 604) (A) in which 12 genes are highly 932 
active (red circles, expression and significance cut-offs, 2.0 and 0.1). The pathway is illustrated 933 
according to subcellular localization and includes the total 255 genes annotated in the pathway. 934 
The bladder transcriptome also includes chemokine-signaling (innateDB pathway 4351) (B) with 935 
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activation of the pathway occurring via 8 genes (red circles, Cxcl10, Cxcl9, Stat2 shown twice) 936 
among a total of 175 genes in the pathway 937 
 938 
Figure 7: Pathogen-specific defense against GBS in the bladder involves fewer gene expression 939 
responses and these are slower to develop than responses elicited by UPEC. Volcano scatterplots 940 
(A) and (B) illustrate significant genes identified by shrinkage t-test results at 2h and 24h for 941 
GBS, compared to those for UPEC (C) and (D). Red stars represent genes at FDR<0.05 for both 942 
pathogens underscoring the more limited response induced by GBS. Significant changes in gene 943 
expression for those genes identified as common (i.e. induced by both GBS and UPEC in the 944 
bladder after 24h) are denoted by black stars in (B) and (D) and are listed in detail in Table 4. 945 
These shared responses illustrate the exact combination of common and pathogen-specific 946 
responses in murine UTI due to these two organisms 947 
 948 
Figure 8: Bladder uroepithelial cells contribute to defense against GBS through production of 949 
chemokines and cytokines. Human 5637 uroepithelial cells were infected with GBS at a MOI of 950 
10 as described in Methods, and culture supernatants at 0.5h, 2h and 24h were used to measure a 951 
panel of 8 targets, identified from microarray data and histopathology as part of the bladder 952 
response to GBS. Data derived from multiplex protein assay are shown for each target and 953 
represent the mean ± SEM for quadruplicate samples versus control (non-infected) bladder cells 954 
  955 
 956 
 957 
 958 
 959 








  
Table 1 - qRT-PCR data for selected genes identified as significantly changed or unchanged in 
expression at 2h and 24h post-infection in bladder during GBS cystitis according to microarrays  
Target 
Gene* 
Time 
Point 
Control Mean ct 
±SEM (n=5) 
Infected Mean  ct 
±SEM (n=5) 
∆ct Fold 
Change 
p Value‡ 
CXCL10 2h 34.111±1.29 33.351±0.53 0.75 1.411 0.110 
 24h 35.208±3.14 28.019±6.82 7.189 30.75 0.001 
iNOS 2h 36.73±1.25 36.75±2.02 -0.02 -1.082 0.817 
 24h 35.73±0.44 32.26±2.81 3.47 11.92 0.001 
CCL5 2h 28.37±1.40 28.425±1.02 -0.055 1.4 0.153 
 24h 29.192±1.15 28.015±1.21 1.177 2.525 0.003 
CXCL5 2h 35.34±0.87 35.21±2.45 0.13 1.13 0.717 
 24h 35.64±0.56 33.73±1.80 1.91 4.96 0.001 
CXCL9 2h 35.573±0.81 34.213±3.57 1.36 1.777 0.075 
 24h 36.753±1.32 31.950±2.78 4.803 6.464 0.008 
IL-1α 2h 31.717±1.05 30.737±3.19 0.98 2.788 0.001 
 24h 32.655±0.95 29.012±2.05 3.643 22.11 0.001 
IL-1β 2h 27.766±1.11 25.343±1.87 2.423 7.58 0.001 
 24h 29.455±2.35 24.013±3.15 5.442 21.096 0.001 
IL-6 2h 33.47±5.70 30.77±10.9 2.5 7.913 0.001 
 24h 37.03±1.34 33.07±6.22 3.14 17.94 0.001 
EMR1 2h 28.06±0.12 28.40±0.38 0.4 1.072 0.824 
 24h 34.48±2.68 33.14±1.02 1.34 2.521 0.124 
CSF1R 2h 22.16±0.06 22.60±.02 0.44 1.51 0.3965 
 24h 28.02±1.3 27.22±0.69 0.8 1.73 0.1995 
INFGr1 2h 33.097±0.33 33.110±0.62 -0.013 1.103 0.5395 
 24h 35.340±3.68 33.477±0.62 1.863 1.12 0.4805 
Caspase-3 2h 30.91±0.63 31.25±1.17 -0.34 -1.089 0.724 
 24h 30.92±1.27 30.64±1.11 0.28 1.293 0.3005 
β-actin 2h 19.938±0.22 20.256±0.13 -0.318 0.815 0.1135 
 24h 20.26±0.31 20.36±0.15 -0.1 0.937 0.1275 
GAPDH 2h 20.162±0.3 20.662±0.43 -0.5 -1.18 0.5 
 24h 20.531±0.23 20.352±0.25 0.179 1.132 0.658 
* Primer sequences listed in supplementary Table S1. 
‡p values compare GBS-infected group with control (PBS) group within each time point, as per Methods 
Table 2 - Global gene expression in bladder during GBS cystitis in mice comprises a significant 
gene list of 172 genes (FDR<0.1) derived from pair-wise comparisons of infected mice with 
control mice (n=5) at 24h post-infection 
Gene Assignment Gene Name Fold Change FDRa 
NM_021274  Cxcl10  25.4 0.006 
NM_008324   Indo  14.87 0.006 
NM_011579   Tgtp  10.94 0.019 
NM_021792   Iigp1  10.55 0.015 
NM_008361   Il1b  10.12 0.011 
NM_011410   Slfn4  9.42 0.015 
BC034256   Tgtp  8.75 0.011 
NM_011260   Reg3g  8.7 0.075 
XM_905096   Irgb10  7.92 0.015 
L38281   Irg1  7.03 0.011 
NM_008620   Gbp4  6.89 0.022 
NM_008331   Ifit1  6.81 0.031 
NM_008326   Irgm  6.54 0.015 
BC112328   LOC626578 6.51 0.022 
NM_011315   Saa3  6.44 0.046 
NM_009114   S100a9  6.38 0.035 
NM_018738   Igtp  6.35 0.018 
NM_144559   Fcgr4  5.94 0.053 
NM_011407   Slfn1  5.83 0.026 
NM_010999   Olfr56  5.75 0.025 
NM_020498   Ly6i  5.71 0.035 
NM_153564   Gbp5  5.48 0.022 
NM_177162   9930032O22Rik 5.43 0.047 
NM_010260   Gbp2  5.42 0.022 
NM_029499   Ms4a4c  5.41 0.079 
ENSMUST031549   EG240327  5.3 0.051 
NM_021394   Zbp1  5.04 0.051 
NM_011346   Sell  4.96 0.044 
NM_010927   Nos2  4.74 0.015 
NM_153511   Il1f9  4.7 0.033 
NM_133871   Ifi44  4.65 0.044 
NM_009099   Trim30  4.62 0.035 
NM_009283   Stat1  4.5 0.03 
NM_172777   BC057170  4.45 0.046 
NM_010501   Ifit3  4.33 0.035 
NM_009141   Cxcl5  4.27 0.071 
NM_023137   Ubd  4.22 0.035 
NM_011472   Sprr2f  4.09 0.057 
NM_021384   Rsad2  4.07 0.044 
NM_018734   Gbp3  4.05 0.048 
NM_145545   Gbp6  4.03 0.047 
NM_016850   Irf7  4.02 0.056 
NM_010819   Clec4d  4 0.077 
NM_008599   Cxcl9  3.99 0.075 
NM_020557   Tyki  3.96 0.025 
NM_008230   Hdc  3.91 0.068 
NM_008462   Klra2  3.87 0.068 
NM_013532   Lilrb4  3.87 0.083 
NM_008329   Ifi204  3.83 0.068 
NM_011854   Oasl2  3.78 0.035 
NM_010554   Il1a  3.72 0.035 
NM_023386   Rtp4  3.7 0.041 
NM_145226   Oas3  3.57 0.022 
AB112025   Sirpb1  3.52 0.088 
NM_021893   Cd274  3.49 0.015 
NM_028595   Ms4a6c  3.43 0.078 
XR_033405   LOC546714 3.43 0.094 
NM_025777   Duoxa2  3.41 0.046 
NM_023044   Slc15a3  3.38 0.047 
NM_008390   Irf1  3.37 0.047 
NM_013563   Il2rg  3.35 0.048 
NM_008491   Lcn2  3.34 0.079 
NM_031168   Il6  3.31 0.094 
NM_008332   Ifit2  3.3 0.051 
EF660528   AW112010  3.27 0.046 
NM_029509   5830443L24Rik 3.26 0.068 
NM_009251   Serpina3g  3.19 0.069 
NM_011157   Srgn  3.15 0.053 
NM_001040005  Rnf213  3.15 0.077 
NM_145227   Oas2  3.13 0.058 
NM_019963   Stat2  3.11 0.035 
NM_001039530  Parp14  3.07 0.088 
NM_139198   Plac8  3.06 0.094 
NM_011347   Selp  3.05 0.075 
NM_133990   Il13ra1  3.04 0.088 
NM_183201   Slfn5  3.03 0.091 
NR_003508   Mx2  3.01 0.081 
AK220210   Nlrc5  2.98 0.035 
NM_018851   Samhd1  2.96 0.057 
NM_011408   Slfn2  2.93 0.069 
NM_013683   Tap1  2.87 0.075 
NM_011909   Usp18  2.86 0.046 
NM_011331   Ccl12  2.86 0.078 
ENSMUST051264   Cd300lf  2.85 0.082 
NM_008848   Pira6  2.84 0.078 
NM_030253   Parp9  2.83 0.058 
NM_001013371  Dtx3l  2.8 0.046 
NM_027835   Ifih1  2.8 0.09 
NM_001038604  Clec5a  2.78 0.083 
NM_001033308  BC013712  2.74 0.066 
NM_010259   Gbp1  2.67 0.029 
NM_011852   Oas1g  2.65 0.079 
NM_010553   Il18rap  2.59 0.066 
NM_029084   Slamf8  2.58 0.044 
NM_172893   Parp12  2.51 0.053 
NM_181754   Gpr141  2.5 0.049 
NM_013673   Sp100  2.48 0.09 
ENSMUST047498  AA467197  2.47 0.043 
NM_145209   Oasl1  2.38 0.098 
NM_008152   Gpr65  2.32 0.083 
NM_008348   Il10ra  2.29 0.078 
NM_010747   Lyn  2.26 0.046 
NM_172689   Ddx58  2.22 0.061 
NM_001024134  Trim15  2.22 0.069 
NM_145133   T2bp  2.19 0.075 
NM_009890   Ch25h  2.19 0.078 
NM_019401   Nmi  2.17 0.078 
BC117807   Ibrdc3  2.1 0.035 
NM_013653   Ccl5  2.1 0.044 
NM_026913   Mitd1  2.1 0.056 
NM_001013817  Sp140  2.02 0.07 
NM_009277   Trim21  1.99 0.078 
NM_008217   Has3  1.88 0.083 
NM_030701   Gpr109a  1.84 0.089 
AK034303   9330175E14Rik 1.82 0.044 
NM_145391   Tapbpl  1.82 0.078 
NM_031167   Il1rn  1.82 0.082 
NM_207648   H2-Q6  1.8 0.056 
NM_030720   Gpr84  1.73 0.092 
NM_001001495  Tnip3  1.73 0.099 
NM_011530   Tap2  1.71 0.075 
NM_183162   BC006779  1.71 0.078 
NM_145373   Sectm1a  1.66 0.058 
NM_175397   Sp110  1.59 0.099 
NM_001033339  Mmp25  1.5 0.068 
NM_024495   Car13  1.43 0.098 
NM_010380   H2-D1  1.35 0.083 
NM_198013   Cuedc1  0.79 0.1 
NM_001085492  Rere  0.78 0.083 
NM_181039   Lphn1  0.77 0.058 
NM_173186   Tbc1d24  0.76 0.082 
NM_172619   Adamts10  0.74 0.04 
NM_007405   Adcy6  0.74 0.046 
NM_173788   Npr2  0.74 0.046 
NM_198300   Cpeb3  0.74 0.079 
NM_032418   Dmpk  0.74 0.091 
NM_177030   Dock6  0.73 0.035 
NM_029967   Adamtsl1  0.72 0.025 
NM_011242   Rasgrp2  0.72 0.083 
NM_053097   Cml3  0.72 0.083 
NM_011066   Per2  0.71 0.071 
XM_990451   AU042671  0.71 0.088 
NM_173749   E430002G05Rik 0.71 0.092 
NM_134437   Il17rd  0.7 0.066 
NM_001042779  Sema3b  0.7 0.088 
NM_011218   Ptprs  0.69 0.051 
BC057903   Col6a3  0.69 0.064 
NM_022814   Svep1  0.69 0.081 
NM_007496   Zfhx3  0.68 0.035 
NM_175473   Fras1  0.67 0.1 
NM_177030   Dock6  0.66 0.058 
NM_008483   Lamb2  0.66 0.083 
NM_053185   Col4a6  0.65 0.015 
NM_031176   Tnxb  0.65 0.078 
NM_027890   Susd2  0.64 0.05 
NM_001033323  Igsf9b  0.64 0.071 
NM_007463   Speg  0.64 0.078 
NM_001012765  Adcy5  0.63 0.056 
NM_001033476  Ahnak2  0.62 0.029 
NM_013630   Pkd1  0.62 0.046 
NM_012040   Pnck  0.62 0.088 
NM_010570   Irs1  0.6 0.027 
NM_013568   Kcna6  0.6 0.09 
NM_175750   Plxna4  0.59 0.015 
NM_139001   Cspg4  0.58 0.09 
NM_008742   Ntf3  0.57 0.071 
XR_034431   LOC100048255 0.56 0.058 
XR_034431   LOC100048255 0.55 0.035 
NM_052835   Rpl10  0.55 0.084 
NM_009154   Sema5a  0.54 0.014 
NM_009204   Slc2a4  0.54 0.035 
NM_176922   Itga11  0.54 0.083 
    
aFDA, false discovery rate. 
 
 
 
Table 3 
Activation of diverse KEGG regulatory networks in bladder during GBS cystitis  
KEGG No. Pathway p Value 
00561 Glycerolipid metabolism 0.01 
00562 Inositol phosphate metabolism 0.01 
00630 Glyoxylate and dicarboxylate metabolism 0.01 
02010 ABC transporters 0.01 
04510 Focal cell matrix adhesion 0.01 
04512 Extracellular matrix-receptor interaction 0.01 
04620 Toll-like receptor signaling 0.01 
04650 Natural killer cell mediated cytotoxicity 0.01 
04662 B cell receptor signaling 0.01 
04810 Regulation of actin cytoskeleton 0.01 
04920 Adipocytokine signaling 0.01 
04010 MAPK signaling 0.014 
04930 Type II diabetes mellitus 0.014 
05060 Unknown 0.017 
00620 Pyruvate metabolism 0.018 
03320 Peroxisome proliferator-activated receptors 0.018 
04210 Apoptosis 0.02 
00970 Aminoacyl-tRNA biosynthesis 0.023 
04670 Leukocyte transendothelial migration 0.023 
05020 Unknown 0.023 
03450 Non-homologous end-joining 0.028 
00480 Glutathione metabolism 0.03 
00220 Urea cycle and metabolism of amino groups 0.033 
00980 Metabolism of xenobiotics by cytochrome P450 0.033 
00982 Drug metabolism - cytochrome P450 0.033 
05222 Small cell lung cancer 0.033 
04060 Cytokine-cytokine receptor interaction 0.035 
04742 Taste transduction 0.035 
04612 Antigen processing and presentation 0.036 
04630 Jak-STAT signaling 0.039 
04660 T cell receptor signaling 0.04 
04912 Gonadotropin-releasing hormone signaling 0.04 
00790 Folate biosynthesis 0.042 
04664 Fc epsilon RI signaling 0.048 
 
